Mirum Pharmaceuticals Inc
MIRMHealthcare|Biotechnology|USA
$122.13
-5.67 (-4.44%)
Upcoming Data Readouts (9)
Apr 2027
Est. completion
P2Primary Biliary Cholangitis
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136n=260
Jun 2027
Est. completion
P3Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
NCT07200908n=172
Aug 2027
Est. completion
P2P3Chronic Hepatitis D
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
NCT07454837n=120
Oct 2027
Est. completion
P2Fragile X Syndrome
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462n=60
Sep 2028
Est. completion
Alagille Syndrome
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928n=70
May 2029
Est. completion
P2P3Chronic Hepatitis D Infection
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
NCT06907290n=150
Sep 2030
Est. completion
P4Alagille Syndrome
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
NCT07290257n=230
Mar 2031
Est. completion
PFIC - Progressive Familial Intrahepatic Cholestasis
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
NCT07411716n=220
Jul 2038
Est. completion
Awaiting Results (3)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P3
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768Aug 2026
P3
A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)
NCT07298330Jun 2026
P2
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
NCT04663308